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What’s already known about this topic? 
• Translational research aims to advance patient care by bridging the gap between laboratory-
based science and clinical dermatology, leading to greater understanding of disease, the 
identification of biomarkers and development of novel therapies.  
• There is a need for a co-ordinated approach to translational research in dermatology in 
order to make the best use of limited resources. 
• The Delphi (or eDelphi; electronic Delphi) technique is used to help develop consensus 
opinion on a topic, and is a useful approach to assist with prioritisation of research questions 
in translational dermatology.  
 
What does this study add? 
• This eDelphi has prioritised a number of translational dermatology research questions which 
are considered by professional and lay experts to be relevant, important and urgent 
priorities. 
• It is anticipated that the knowledge generated through pursuing these research questions 
will lead to significant benefits for individuals affected by skin disease.  
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Summary 
Background: Translational research is the direct application of basic and applied research to 
patient care.  It is estimated that there are at least 2,000 different skin diseases, thus there are 
considerable challenges in seeking to undertake research on each of these disorders. 
Objective: This eDelphi exercise was conducted in order to generate a list of translational 
dermatology research questions which are regarded as a priority for further investigations. 
Results: During the first phase of the eDelphi, 228 research questions were generated by an expert 
panel which included clinical academic dermatologists, clinical dermatologists, non-clinical 
scientists, dermatology trainees and representatives from patient support groups. Following 
completion of the second and third phases, 40 questions  on inflammatory skin disease, 20 
questions  on structural skin disorders / genodermatoses, 37 questions  on skin cancer and 8 
miscellaneous questions  were designated as priority translational dermatology research questions 
(PRQs).  In addition to PRQs on a variety of disease areas (including multiple PRQs on psoriasis, 
eczema, squamous cell carcinoma (SCC) and melanoma), there were a number of cross-cutting 
themes which identified a need to investigate mechanisms / pathogenesis of disease and the 
necessity to improve treatments for patients with skin disease.  Conclusion: It is predicted that this 
list of PRQs will help to provide a strategic direction for translational dermatology research in the 
UK and that addressing this list of questions will ultimately provide clinical benefit for substantial 
numbers of subjects with skin disorders. 
 
Introduction 
Skin disease is extremely common and it is estimated that at least 2,000 different dermatological 
disorders exist1.  In the UK, approximately 54% of the population are affected by dermatological 
conditions each year2.  These skin conditions vary in presentation, prevalence, and impact. For 
example, 2% of the population suffer from psoriasis, while up to 32% of children have atopic 
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eczema and nearly all teenagers develop acne vulgaris3-5.  In addition, skin cancer is the most 
common cancer in the UK, as well as globally, despite evidence of under-reporting of skin cancer 
in national databases6,7.  As might be expected, skin disease can impact significantly on patients’ 
and their relatives’ quality of life, with a recent study on global burden of disease indicating that 
skin conditions are the fourth leading cause of nonfatal disease burden worldwide8-10.  
While there is a clear need to develop laboratory-based research to better understand the 
underlying causes of these skin conditions, to date there has been a lack of a strategic focus within 
dermatological research that aims to ‘translate’ new findings and discoveries into new drugs, 
diagnostic aids, devices and treatment options for patients, and to make sure that these new 
principles actually impact on patient care and public health.  Indeed, while the rate of basic 
research ensures that the scientific knowledge base is constantly increasing, there is a substantial 
lag with respect to the rate at which this is translated into improved health and wellbeing.  
Translational research seeks to bridge this gap, applying basic science concepts to solve ‘real 
world’ problems; as such, translational research takes a patient-centred or patient-oriented 
approach and is in-keeping with recent developments in health policy11.  In addition to this lag 
between basic research and the clinical implementation of findings, the ability to undertake 
translational research on the full range of skin disorders is limited at the present time.  This 
limitation raises important issues regarding how best to improve patient care for skin disorders.   
Given the large number of heterogeneous dermatological conditions and limited resources 
with which to fund translational research in dermatology, the UK Translational Research Network in 
Dermatology (UK TREND) was established by the British Association of Dermatologists (BAD) in 
order to “support, facilitate and further develop internationally-leading, translational research in skin 
biology and skin disease across the UK for the direct benefit of patient care”12.  As part of this 
mandate, a translational research prioritisation exercise was undertaken, with the goal of 
identifying and prioritising important research questions for translational advances that can be 
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achieved in order to provide practical steps that will help to expedite the basic to translational step 
within the research pipeline.  
The Delphi approach is a method for structuring a group communication process to enable a 
group of individuals, as a whole, to deal with a complex problem13,14.  This technique, first reported 
in 1963, has been employed for over half a century to gain consensus opinion in multiple 
situations, ranging from views on transformative drugs developed by the pharmaceutical industry to 
forecasting population migration15-17.  Likewise, the Delphi has been used to assist in the planning 
of education, including the dermatological content of the undergraduate medical curriculum18-20.  
More recently, the Delphi has been utilised to prioritise research in various medical specialties, 
including occupational medicine, respiratory medicine, and mental health21-23.  
 In the current study, members of UK TREND conducted an electronic Delphi (e-Delphi) 
exercise to help prioritise translational research in dermatology.  The results highlight many 
translational research questions which are important, practical and feasible to address at the 
current time, and from which the results are ultimately likely to lead to substantial benefits for 
patients with skin diseases. 
 
Materials and methods 
UK TREND was established by the BAD as a company limited by guarantee (not for profit 
organisation). The e-Delphi project was directed by the steering group of UK TREND which has full 
academic freedom. 
 
Participants in the survey 
Participants were eligible for inclusion if they were stakeholders in the translation lifecycle of 
dermatological research. This included researchers, clinicians and knowledge users (patients and 
policy makers). Individuals were identified by the steering group of UK TREND and invited to 
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participate in the Delphi expert panel because they had extensive experience in clinical 
dermatology and translational research (17 senior clinical academic dermatologists), clinical 
dermatology (4 NHS consultant dermatologists), or in translational research in dermatology (3 
senior non-clinical scientists).  Patients with skin disease were also invited to participate (3 
representatives from broad-based patient support groups dealing with all types of skin disease), as 
well as representatives from primary care (1 clinical academic general practitioner who also sought 
input from the Dermatology Specialist Interest Group, Society for Academic Primary Care), two 
senior members of the British Association of Dermatologists (i.e. members of the BAD Executive 
Committee) and clinical trainees (2 trainees in dermatology).  As the Delphi process is an 
exploratory technique, and not intended to generate statistically representative samples nor identify 
differences between groups, sample size calculations to determine the number of expert panel 
members were not performed.  Given the geographic dispersion of the expertise within the UK, 
invitations were made via email. This approach achieved an expert panel with representation that 
covered a wide geographical area within the UK (Fig. 1).  
 
Surveys 
As per the Delphi structure, the translational dermatological research eDelphi was conducted in 
three phases.  In the first phase participants provided open-text responses detailing important 
research questions. This was followed by consolidation of responses that were subsequently rated 
for importance. Following the initial ratings, a second round of rating was undertaken in order to 
achieve a final list of “priority translational dermatology research questions” (PRQs). 
During phase 1, participants were asked to provide up to 15 questions about translational 
research topics covering the breadth of dermatology across the following four categories; (i) 
inflammatory skin disease, (ii) structural skin disorders / genodermatoses, (iii) skin cancer and (iv) 
miscellaneous.  Participants were encouraged to request input from colleagues within their 
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departments in order to ensure that there was broad input into the generation of the questions.  
The definition of translational research provided to participants was that used by UK TREND, i.e. 
“the direct application of basic and applied research to patient care;  this may encompass 
diagnostics, biomarkers, disease mechanisms and the development of new therapies that then 
impact on clinical practice”12. To assist with the production of questions, participants were informed 
that questions could deal with disease processes such as aetiology, pathogenesis, diagnosis 
(including biomarkers), treatment, and burden of disease, but it was highlighted that questions on 
any aspect of translational dermatology research were encouraged. 
  In the second phase, a consolidated list of research questions produced in the first phase, 
maintained under the same four headings, was circulated via Survey Monkey® to all participants 
on the expert panel. Participants were asked to score each question in each section on a 5-point 
Likert-type scale from 1 to 5, where 5 indicated a very important research question and 1 indicated 
a least important question.  Again, participants were encouraged to complete the scoring of 
questions with input from members of their department.  In addition, participants were informed that 
the scores would subsequently be collated and that they would each be provided, during phase 3, 
with the average score and with their own score for each question, with the ability to modify their 
score at that stage if they wished. 
In the third phase, and in order to facilitate the consensus process and minimise participant 
burden, participants who took part in phase 2 were provided the top questions (mean score ≥ 3.0) 
identified in each of the four categories and asked to review the mean and median scores for each 
of these higher ranking questions together with their own score. Participants were informed that 
they could modify their score, if they wished to do so, using the same 5-point Likert-style scale as 
the previous round. During phase 3, these higher scoring questions were left in the same original 
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order in each of the categories so as to minimise any bias when the questions were recirculated to 
participants (i.e. ranking by mean or median score was not provided). 
 
Data Analysis 
Following phase 1, duplicate or closely duplicated questions were received in some cases, 
therefore these were reviewed and combined by members of the eDelphi study group (EH, SJB, 
ST, KS, SML, NJR) in a manner to preserve all components of the original questions.  In certain 
cases, where statements rather than questions were received, the participants who had provided 
these statements were asked to convert them into questions. When questions potentially related to 
more than one category, their designated category was that deemed to be the primary focus as 
determined by the members of the eDelphi study group.  As such, although the research questions 
were listed in one of the four categories, the groupings were not mutually exclusive and PRQs 
relevant to some skin disorders may have appeared under different categories.    
Quantitative data were summarised using the mean and median score for each question.  In 
order to achieve consensus on a manageable number of research priorities, a pre-defined criterion 
of consensus was established. It was considered that if at least 70% of participants scored a 
question as ≥ 3.0 during the third phase, this would be deemed to be indicative that consensus had 
been achieved that the question should be regarded as being of high priority by the majority of the 
panel. Questions meeting this criterion were designated as “priority translational dermatology 
research questions (PRQs)”. 
 
Results 
During phase 1, a total of 240 questions were provided by 19 members of the expert panel (Fig. 2).  
Following removal of duplicate questions, a consolidated list of 228 research questions remained.  
These included 68 on inflammatory skin disease, 44 on structural skin disorders / genodermatoses, 
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68 on skin cancer and 48 under the miscellaneous category.  The 228 questions were sent to the 
32 members of the expert panel during phase 2 and completed scores for all questions were 
returned by 27 members of the expert panel (response rate 84.4%).  Mean and median scores 
were calculated for all questions, with 122 questions attaining a mean score of ≥ 3.0; this 
comprised 47 inflammatory skin disease, 22 structural skin disorders / genodermatoses, 41 skin 
cancer and 12 miscellaneous category questions.   
Phase 3 was completed by 23 participants (response rate 23/27 = 85.2%), with a total of 
105 questions achieving consensus (which we defined as 70% of respondents scoring the question 
≥ 3.0). These comprised 40 questions on inflammatory skin disease, 20 on structural skin disorders 
/ genodermatoses, 37 on skin cancer and 8 miscellaneous questions, i.e. a total of 105 PRQs 
(supplementary table 1).   
In the inflammatory skin disease component, PRQs on inflammatory skin diseases in 
general as well as on eczema/dermatitis (including atopic eczema) and psoriasis were common, 
but those on other specific disorders included hidradenitis suppuritiva, lichen planus, cutaneous 
lupus (erythematosus), toxic epidermal necrolysis and drug allergy (table1 and supplementary 
table 1).   
Many of the PRQs in the structural skin disorders / genodermatoses category were related 
to the underlying genetics of common and rare skin disorders or to the development of genetics-
based technological approaches to treating a variety of skin diseases (table 2 and supplementary 
table 1).  Indeed, treatments emerged strongly as cross-cutting themes in each of the four 
categories, as did mechanisms / pathogenesis of disease (which can inform development of novel 
therapies), and these mechanism / treatment themes were also noted in the PRQs on ulceration 
and wound healing which were present in the structural skin disorders / genodermatoses category.   
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In the skin cancer component, PRQs tended to focus more on SCC and melanoma, 
however, basal cell carcinoma, cutaneous lymphoma, dermatofibromasarcoma protuberans and 
Merkel cell carcinoma also featured (table 3 and supplementary table 1).   
Some of the PRQs in the miscellaneous section dealt with inflammatory skin disease, 
genetic aspect of disease or skin cancer, but research questions on vitiligo and itch were also 
considered as priorities by the participants (supplementary table 1). 
 
Discussion 
The focus of this eDelphi was on the prioritisation of translational dermatology research questions.  
In the case of dermatology, there are challenges in prioritising research while, at the same time, 
avoiding discrimination between common and rare diseases.  It is also recognised that prioritising 
research is likely to influence not only the focus of current investigations but also the future 
direction of research, as well as having the potential to inform future funding directions.  Whereas 
not all participants provided questions, all members of the expert panel were invited to score the 
questions during phase 2, thus ensuring that the scoring was broadly representative of the panel 
membership.  Although the total number of questions submitted by the participants may appear 
limited in comparison with the total number of skin disorders that exist, there were several cross-
cutting themes (e.g. genetics, molecular, immune, therapeutic, biomarkers) in the original 
questions supplied by members of the expert panel and in the final list of PRQs.  Indeed, 
noticeable themes that ran through each of the pre-determined categories was the potential for 
treatment, and for translational research to build upon information obtained from the molecular and 
cellular pathogenesis of skin disease (e.g. genomic, immunological, etc.) in order to generate 
biomarkers and develop new therapies.  In addition, there was a strong emphasis on personalised 
medicine (also referred to as precision or stratified medicine)24,25 related to patient outcome in 
terms of treatment efficacy or risk of disease complications.  Recent research to classify 
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scleroderma patients on the basis of gene expression profiles is consistent with this stratified 
medicine approach26. 
Interestingly, many PRQs have relevance to other clinical specialties, for example psoriasis 
is a multisystem disease and translational advances in this skin disorder are potentially applicable 
to psoriatic arthritis and other arthritides, including rheumatoid arthritis.  Similarly, progress in the 
translational aspects of atopic eczema may impact clinically on the atopic march, asthma and hay 
fever as well as understanding how environmental allergens can modify innate / acquired immune 
function at various epithelial surfaces.  Likewise, translational advances in skin cancer may provide 
insight into genetic and immunological factors which determine clinical outcome from cancer, and 
from precancerous lesions, in general.  Moreover, the relevance of the PRQs to other disciplines 
and the benefits of interactions with scientists in other disciplines highlight the advantages of a 
multidisciplinary approach in addressing these PRQs. 
 Within each of the pre-determined categories, important trends were notable.  In the 
inflammatory skin disease group, PRQs on eczema and psoriasis were common, which may reflect 
the research interests of invited and contributing participants.  The interest in psoriasis is despite 
the fact that significant translational improvements have already been made in psoriasis over the 
past 15 years27, with the PRQs demonstrating that there remains a need for further progress, and a 
view that progress is feasible, in the bench-to-bedside impact of research on this disorder.  That 
eczema features prominently may relate to the limited treatment options, high prevalence and 
significant morbidity of atopic eczema and other forms of dermatitis.  The frequent PRQs on this 
condition may also be influenced by the fact that dermatologists have recently seen gains in the 
understanding and treatment of psoriasis and thus wish to see similar advances in eczematous 
disorders.  These PRQs on eczema also complement the prioritized treatment uncertainties 
reported by Batchelor et al. as part of an eczema priority setting partnership28.  Furthermore, recent 
progress in understanding the genetic basis of the skin barrier defect as an underlying mechanism 
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in atopic eczema has stimulated interest in the translation of this for development of therapy and 
clinical trial stratification29,30.  The structural skin disorders / genodermatoses grouping of PRQs 
exhibit an important underlying theme which is applicable to each of the four categories, namely 
the relevance to all skin diseases of understanding the impact of genetic alterations on disease 
phenotype and the development of novel therapeutic genetic / cellular approaches to improve 
patient care.  Indeed, some early promising results have recently been seen with the use of genetic 
and cellular-based therapies for certain monogenic skin diseases, forming a strong translational 
foundation upon which to build future advances31,32. 
In the skin cancer category, PRQs on melanoma and SCC were most common, which may 
relate to the increasing burden of disease in terms of mortality and long-term clinical follow-up for 
higher risk cases with these tumours33,34.  There is also recognition that, whereas surgery remains 
an important therapeutic option for many skin cancers, there is a need for alternative and additional 
treatments for precancerous lesions and more aggressive cancers respectively35,36. While recent 
advances have been observed with novel pharmacological therapies for metastatic melanoma37, 
these are generally not curative; in addition, limited progress has been made in the treatment of 
SCC over the past few decades38,39.  Not surprisingly, the need for a stratified medicine approach 
to skin cancer, similar to the strategy for treatment of inflammatory skin diseases, was noted.  In 
contrast to skin cancers, inflammatory skin diseases and structural skin disorders / 
genodermatoses, it is difficult to categorise many other skin diseases under these terms.  For 
example, although genetic and immunological factors are involved in the development of vitiligo40, 
this disease is not generally viewed as a classical inflammatory or genetic skin disorder.  Thus, the 
use of the miscellaneous category for a number of the questions in the eDelphi was helpful 
because it ensured that PRQs could be generated on any type of skin disease and that all 
dermatological disorders were covered by the prioritisation process. 
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We are aware that any attempt to conduct a detailed analysis of the results of this eDelphi is 
fraught with difficulty.  In addition, the findings of this exercise must be considered within the 
limitations of the eDelphi approach. Given the limited number, and select group of participants, 
there is the potential for bias due to the research interests of the participants and/or their 
departments. To mitigate this we purposively sought expertise and input from a wide range of 
individuals and from across a wide geographical area and we actively encouraged participants to 
seek input from colleagues at each centre / institution. Although we did not specifically ask the 
panel members to report on this issue, we are aware from verbal feedback that a number of the 
panel members did seek input from several colleagues (including medical and nursing colleagues) 
in their department.  The exercise is also open to the vagaries of current areas of interest that are 
in vogue. Indeed, as translational research progress is made on the above PRQs, it is probable 
that translational research priorities will change and it is recognised that this eDelphi reports on 
current PRQs and that updating the eDelphi exercise in the future will ensure that translational 
dermatology research remains strategically focussed in the long-term. 
The results of this eDelphi are likely to impact on several areas relevant to improving patient 
care.  Firstly, it is recognised that the existence of at least 2,000 different dermatological disorders 
makes it difficult for research funding organisations to determine priorities for research funding in 
this discipline, thus it is anticipated that the list of PRQs will assist in this process.  Secondly, the 
eDelphi can be employed to facilitate the development of strategic translational dermatology 
research clusters within the UK (for example on eczema, SCC, etc.) akin to the BADBIR cluster on 
psoriasis which has been instrumental to improving many aspects of patient care41.  Thirdly, the 
direction of translational research provided by the PRQs will impact on research training in 
dermatology, both for those wishing to train as clinical academics and for those who plan to work 
primarily in the NHS in future years.  Fourthly, it is probable that the PRQs will be useful to the 
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pharmaceutical and biotechnology industries in their role of developing new therapeutics and 
biomarkers for skin disease. 
In conclusion, the results of this eDelphi highlight a number of translational research 
questions which are considered priority areas, because they have the potential to bridge the gap 
between basic laboratory research and enhancing patient care, thus improving the health and well-
being of individuals with skin disease. 
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Supplementary table 1 containing full list of questions with 70% respondents ranking as ≥ 3.0 (i.e. 
priority translational dermatology research questions). 
 
 
Figure legends 
 
Fig 1.  Geographical distribution of participants on the eDelphi expert panel.  
 
Fig 2.  Flow diagram illustrating the process used to conduct the eDelphi on translational 
dermatology research priorities. 
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Table 1: Top 10 priority translational dermatology research questions on inflammatory skin disease 
(listed in alphabetical order). 
Can we develop a reliable test for identifying the culprit drug in drug allergy? 
Can we identify novel systemic treatments for adult eczema? 
Can we predict (from genotype and/or phenotype) which patients will respond to which 
second/third line treatments for eczema and which patients will not respond? 
Can we stratify systemic/biological treatments on the basis of genotype and/or phenotype and 
predict treatment outcome in psoriasis? 
Do biological therapies for major inflammatory skin diseases have long-term side effects? 
Does restoration of barrier function in atopic dermatitis prevent immune activation, disease 
persistence/progression, and/or the atopic march? 
Does therapeutic increase in filaggrin expression associate with improvement in atopic 
disease? 
How does the environment, the microbiome and epigenetics influence inflammatory skin 
disease? 
What genetic factors other than filaggrin are important in the pathogenesis of atopic 
dermatitis? 
What mechanism underlies children growing out of eczema? 
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Table 2:  Top 10 priority translational dermatology research questions on structural skin disorders / 
genodermatoses (listed in alphabetical order). 
Can the understanding of genetic mechanisms be used to develop novel therapeutics for skin 
disease? 
Can topical formulation deliver siRNA and small molecules to genetically impaired skin? 
Can we improve our mechanistic understanding for acute and chronic wound healing? 
Does early effective skin care prevent or postpone leg ulceration in chronic venous 
insufficiency? 
How can we best correct the effects of genetic alterations which lead to disease (e.g. 
treatment of epidermolysis bullosa, correction of filaggrin deficiency)? 
Is there a single most efficient and safest method for delivery of siRNA gene therapy to the 
skin independent of the condition? 
What angiogenic factors in leg ulcer healing can be exploited therapeutically? 
What are the mechanisms involved in impaired wound healing that can be used to improve 
treatment- diabetic ulcers, venous ulcers? 
What insight do novel genes in the genodermatoses give regarding the molecular 
mechanisms of more common skin disease? 
Does bone marrow transplantation for genetic skin diseases such as RDEB give long term 
persistence of graft cells in the skin and structural repair without immune response? 
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Table 3: Top 10 priority translational dermatology research questions on skin cancer (listed in 
alphabetical order). 
Can the oncogenome of cutaneous SCC be used to predict response to novel targeted 
therapies? 
Can we identify biomarkers of melanoma recurrence / tumour load to assist in the early 
detection of metastases and selecting patients for interventions such as vemurafenib and 
ipilimumab? 
Can we identify novel systemic treatments for SCC? 
Can we identify stratified therapies for melanoma? 
Does the treatment of precancerous skin lesions i.e. actinic keratoses lead to a reduction in 
the development of squamous cell carcinoma? 
What are the critical determinants of the tumour microenvironment that drive aggressive 
cutaneous SCC? 
What are the genetic/molecular drivers for cutaneous SCC? 
What are the predictive biomarkers of melanoma relapse? 
What are the specific biomarkers associated with progress of dysplastic nevi to primary 
melanoma to metastatic melanoma in the same individual? 
What factors drive the survival of melanoma cells that are apparently dormant and that lead to 
metastases, in some cases, decades after excision of the primary lesion? 
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Supplementary table 1:  Full list of questions which were ranked as ≥ 3.0 by 70% respondents 
(designated as priority translational dermatology research questions (PRQs)). 
 
 
Inflammatory skin disease 
Can aggressive treatment of atopic eczema during the first year of life with emollients/topical 
corticosteroids or immunomodulators shorten the duration of disease and prevent the atopic 
march? 
Can biologics be stopped sooner for people with psoriasis, and if so what are the predictors 
for such people? 
Can the development of childhood eczema be prevented or delayed by early identification 
and targeted intervention of high-risk families? 
Can the pathogenesis of classical pyoderma gangrenosum be identified using a genomic 
and biomarker approach (e.g. investigating inflammasome)? 
Can we develop a reliable test for identifying the culprit drug in drug allergy? 
Can we identify novel systemic treatments for adult eczema? 
Can we identify novel systemic therapies for lichen planus? 
Can we modulate lichenoid inflammation and long-term sequelae, such as in lichen sclerosis 
and scarring? 
Can we predict (from genotype and/or phenotype) which patients will respond to which 
second/third line treatments for eczema and which patients will not respond? 
Can we stratify systemic/biological treatments on the basis of genotype and/or phenotype 
and predict treatment outcome in psoriasis? 
Considering their central role in leukocyte recruitment; can chemokines be exploited as 
therapeutic targets is inflammatory skin disease? 
Do biological therapies for major inflammatory skin diseases have long-term side effects? 
Do insights from GWAS analysis of families with psoriasis or atopic eczema give rise to new 
treatments? 
Do patients with atopic eczema really grow out of their disease and what is the burden of 
adult atopic eczema? 
Does restoration of barrier function in atopic dermatitis prevent immune activation, disease 
persistence/progression, and/or the atopic march? 
Does therapeutic increase in filaggrin expression associate with improvement in atopic 
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disease? 
Does tight psoriasis control reduce mortality from co-morbidities? 
How do we develop stratified medicine/personalised therapy in psoriasis and eczema (drugs 
and UV)? 
How do we explain the morphology and distribution of [inflammatory] skin disease? 
How do we improve the correlation between molecular and immunological endotype of 
inflammatory disease and phenotype? 
How does the environment, the microbiome and epigenetics influence inflammatory skin 
disease? 
How effective are systemic treatments in hidradenitis suppurativa? 
What are the environmental factors responsible for the rise in atopic eczema prevalence? 
What are the epigenetic regulatory processes underpinning different forms of skin 
inflammation and their response/resolution? 
What are the immune molecular targets for treating atopic dermatitis? 
What are the mechanisms involved in the pathogenesis of hidradenitis suppurativa? 
What are the mechanisms of cutaneous lupus? 
What are the mechanisms of environmental triggers in the development of psoriasis? 
What are the molecular mechanisms by which filaggrin deficiency results in skin barrier 
impairment? 
What are the most effective systemic treatments for lichen planus? (even placebo controlled 
studies may been needed) 
What are the underpinning processes that determine scarring versus non-scarring in skin 
inflammatory disorders? 
What genetic factors other than filaggrin are important in the pathogenesis of atopic 
dermatitis? 
What is the optimal management of TEN (what locations, what interventions)?  
What is the pathogenesis of rosacea – is there a role for targeted treatments? 
What is the role of genomics and biomarker research in inflammatory skin disease? 
What is the role of personalized medicine approaches? 
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What is the role of vitamin D in inflammatory skin disease? (mechanism of action, genetic 
variation in response etc)? 
What mechanism underlies children growing out of eczema? 
What mechanisms drive Koebnerisation in psoriasis? 
What treatments for psoriasis will affect associated systemic excess disease risk (e.g. 
cardiovascular disease)? 
Structural skin disorders / genodermatoses 
Can novel targets for intervention be found across neglected ichthyoses and keratinisation 
disorders including palmoplantar keratodermas? 
Can the understanding of genetic mechanisms be used to develop novel therapeutics for 
skin disease? 
Can topical formulation deliver siRNA and small molecules to genetically impaired skin? 
Can we build integrated clinical and research networks for rare and complex skin diseases? 
Can we improve our mechanistic understanding for acute and chronic wound healing? 
Does bone marrow transplantation for genetic skin diseases such as RDEB give long term 
persistence of graft cells in the skin and structural repair without immune response? 
Does early effective skin care prevent or postpone leg ulceration in chronic venous 
insufficiency? 
Does rapid genetic diagnosis of genodermatoses via next generation sequencing give any 
patient benefit? 
How can we best correct the effects of genetic alterations which lead to disease (e.g. 
treatment of epidermolysis bullosa, correction of filaggrin deficiency)? 
How do we improve gene therapy for genodermatoses? 
How do we improve models of human skin (to include appendages and stem cells)? 
Is cell therapy useful for severe genodermatoses and can we improve cellular therapies for 
genodermatoses in general? 
Is there a single most efficient and safest method for delivery of siRNA gene therapy to the 
skin independent of the condition? 
Is there a targeted treatment for Darier’s disease / Grover’s disease? 
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What angiogenic factors in leg ulcer healing can be exploited therapeutically? 
What are the genetic bases of disorders of intermediate prevalence such as lichen planus, 
PLC, lichen striatus etc?  
What are the genetic factors affecting efficacy of commonly used drugs such as 
methotrexate, azathioprine other than the obvious ones (i.e. whole genome approach)? 
What are the mechanisms involved in impaired wound healing that can be used to improve 
treatment- diabetic ulcers, venous ulcers? 
What insight do novel genes in the genodermatoses give regarding the molecular 
mechanisms of more common skin disease? 
What is the link between structural breaches in the skin barrier and food allergies? 
Skin cancer 
BAD guidelines for follow up of patients with cutaneous SCC (cSCC) recommend medical 
observation for between 2-5 years. Is this necessary when complete excision of the 
presenting tumour has been undertaken?  
Can the oncogenome of cutaneous SCC be used to predict response to novel targeted 
therapies? 
Can we boost anti-cancer immunity to help treat most NMSCs? 
Can we develop an effective topical therapeutic for BCC? 
Can we identify biomarkers of melanoma recurrence / tumour load to assist in the early 
detection of metastases and selecting patients for interventions such as vemurafenib and 
ipilimumab? 
Can we identify novel systemic treatments for SCC? 
Can we identify stratified therapies for melanoma?  
Does the treatment of precancerous skin lesions i.e. actinic keratoses lead to a reduction in 
the development of squamous cell carcinoma? 
How best can skin cancer in organ transplant recipients be prevented? 
How do cSCC and melanoma develop metastatic potential and does the tumour 
microenvironment have a critical role? 
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How do we develop early biomarkers of skin tumour metastasis? 
How do we develop stratified medicine/personalised therapy for skin cancer? 
How do we explain late recurrences of melanoma, in terms of seed and soil and the nature 
of the immune response to melanocytes and melanoma? 
How do we improve our prediction of cutaneous lymphoma prognosis? 
How will skin tumour dermatopathology be improved by DNA sequencing? 
Is there sufficient molecular, cellular and preclinical evidence to support the use of the 
available targeted treatments against growth factor receptors (e.g. EGFR), PI3K-AKT, or 
MAPK signalling as a therapeutic strategy in cutaneous SCC? 
What are the best prognostic biomarkers in cutaneous SCC in terms of predicting 
metastases? 
What are the biomarkers and genetic factors involved in the transition between photo-aged 
skin, AKs and SCC?  
What are the biomarkers of increased risk of skin cancer in immunosuppressed individuals? 
What are the critical determinants of the tumour microenvironment that drive aggressive 
cutaneous SCC? 
What are the genetic and biological factors in the pathogenesis of infiltrative BCC? 
What are the genetic/molecular drivers for cutaneous SCC?   
What are the genetics and biology of rare skin tumours such as DFSP? 
What are the genotypic differences between patients with single versus multiple primary 
melanomas? 
What are the molecular pathogenic mechanisms underlying field cancerisation and how can  
treatment of sun exposed dysplastic skin reduce the risk of SCC? 
What are the optimal levels of UV-exposure for health and disease at an individual subject 
(rather than population) level to permit us to provide balanced/personalised advice regarding 
sun-exposure? 
What are the predictive biomarkers of melanoma relapse? 
What are the specific biomarkers associated with progress of dysplastic nevi to primary 
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melanoma to metastatic melanoma in the same individual? 
What biomarkers or patient or tumour characteristics predict which actinic keratosis will 
progress to SCC? 
What factors drive the survival of melanoma cells that are apparently dormant and that lead 
to metastases, in some cases, decades after excision of the primary lesion? 
What is the best treatment for Merkel cell carcinoma? 
What is the biological behaviour of different clinical pathological types of melanoma, with 
reference to metastatic potential and the timescale of evolution of melanomas? 
What is the biology of in-situ melanomas? 
What is the natural history of pre-malignant lesions and is treatment necessary? 
What is the optimal staging pathway for people with high-risk melanoma? 
What is the role of reduced skin immunity in the development of non-melanoma skin cancer 
in normal (i.e. non-organ transplant/non-immunocompromised) subjects? 
With the advent of new targeted therapies for the treatment of metastatic melanoma, does 
regular CT surveillance lead to an improvement in overall survival? 
Miscellaneous 
Can cutaneous wart virus infections be prevented by vaccines and can they prevent skin 
carcinogenesis in beta PV infection? 
Can we identify novel intradermal vaccination strategies for cancer and autoimmune 
diseases? 
What are possible new biomarkers of inflammatory skin disease including lichen planus, 
palmoplantar pustulosis, atopic dermatitis, psoriasis? 
What are the mechanisms of action of dermatological therapies (e.g. azathioprine, 
methotrexate, UVB, coal tar, PDT etc.) and can the mechanistic understanding be applied to 
the development of more specific & targetted therapies? 
What are the mechanisms involved in the pathogenesis of vitiligo? 
What are the roles of skin dendritic cells in immune surveillance and disease? 
What is the pharmacology and neurophysiology of itch in man? 
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What underpins apparent protection of depigmented vitiligo skin against UVR associated 
non-melanoma skin cancers? 
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Appendix. Composition of UK TREND 
 
UK TREND consists of: (i) Steering committee: Mike Ardern-Jones (Chairman of British Society for 
Investigative Dermatology), Marilyn Benham (Chief Executive Officer, British Association of 
Dermatologists), Sara Brown (Clinical Academic Representative), Eugene Healy (Deputy 
Chairman, UK TREND), Mike Jaega (Lay Representative), Irene Leigh (Academic Vice President, 
British Association of Dermatologists), Irwin McLean (Non-Clinical Academic Representative), Nick 
Reynolds (Chairman, UK TREND), Emma Rush (Lay Representative), Kave Shams (Research 
Trainee Representative), Shernaz Walton (NHS Clinical Dermatologist Representative) and (ii) 
Advisory committee: Chris Griffiths (Chairman), with other members of Advisory committee 
currently being appointed. 
 
  
 
